Acute myocardial infarction (AMI) is associated with a high mortality rate and a large number of complications (1) . The AMI mortality rate is directly related to the severity of hemodynamic deterioration and can be reduced by rapid reperfusion with chemical agents or mechanical procedures (2) . The main mechanism of improvement is myocardial salvage (3). However, restoration of myocardial function does not depend only on the success of reperfusion therapy. Glucose-insulin-potassium solution (GIK) was proposed for the first time as a polarizing agent promoting electrical stability and protecting heart during AMI (4). Although a meta-analysis of subsequent randomized trials found a 28% reduction of in hospital mortality rates (5) , there are controversial reports about the GIK effect in AMI management. The present study aimed to evaluate the effects of GIK on AMI patients received streptokinase and compare its effects on patients with different Killip classes (KC I vs. II /III).
Present single-blind clinical trial evaluated the effects of GIK on AMI patients admitted to Tabriz Shahid Madani Hospital, Feb 2006-Jul 2007. Study protocol was approved by the ethic committee of Tabriz University of Medical Sciences.
Patients who had symptoms consistent with AMI 20 minutes in duration, presented within 12 hours of symptom onset, and had ST elevation ≥1 mm in two contiguous electrocardiographic leads were enrolled. Exclusion criteria were serum creatinine ≥3 mg/dl, hyperkaliemia, and severe heart failure (KC IV). Patients with diabetes mellitus or plasma glucose level ≥300 mg/ dl were also excluded.
One hundred AMI cases were enrolled; 50 patients into KC-I group and remainder into KC-II/III. The patients underwent streptokinase thrombolytic therapy after admission during at least 12 hours after onset of the symptoms. B group was divided into two subgroups including 25 patients (GIK vs. Placebo group). All included patients received standard therapies for AMI according to European Society Guidelines. The GIK (25 % glucose, 50 IU insulin and 80 mmol/lit potassium chloride) infused with 1mg/kg/h speed for 24 hours simultaneously with streptokinase (1.5 MU during 30-60 minutes).
Left ventricle ejection fraction (LVEF) was determined using transthoracic echocardiography by Simpson's method. Post AMI recurrent MI, mechanical complications, cardiogenic shock, arrhythmia, heart failure (HF), mortality and revascularization were surveyed during hospitalization period, at 1 st , 3 rd and 12 th months after discharge.
Statistical analyses were performed using SPSS software 13.0. Statistical significance between groups of evaluation was estimated using one-way repeated measures ANOVA and Chisquare tests. The p value <0.05 was considered significant.
There were no significant differences between groups in demographic characteristics and clinical manifestation of AMI. Table 1 shows infarct locations and primary LVEF in the study's groups. Considering study design, subjects of KC-I group have high LVEF (p=0.024). The outcome of GIK infusion during follow up period is presented in Table 2 .
During hospitalization. Only three subjects from KC-I 's placebo subgroup complicated with HF (p=0.022), while there were six subjects with HF in both GIK and placebo subgroups of KC-II/III group (p=0.463). Comparison of mortality rate was non-significant.
One month after discharge. Three participants deceased. All these deceased subjects were belonged to KC-II/III in which one had received GIK infusion. Although mortality rate was not different between Placebo and GIK subgroups (p=0.261), it was higher in KC-II/III group (p=0.035).
Three months after discharge. Mortality rate was not different between GIK and Placebo subgroups, and even between KC-I and -II/III groups (p=0.387, 0.815).
Twelve months after discharge. The mortality rate had not changed regarding the rates of previous follow up.
Totally, six participants died; five belonged to KC-II/III group and one was from KC-I (p=0.029). Out of five deceased subjects from KC-II/III group, three and two cases belonged to the Placebo and GIK subgroups, respectively. Mortality rate was not different between subgroups of different KC groups (p=0.315).
Study results showed that the rate of post AMI complications and mortality was not different between GIK and Placebo subgroups according to KCs during follow up, except the rate of HF during hospitalization which was significantly lower in KC-I received GIK.
Initially, Sodi-Pollares et al. (4) showed that GIK reduced mortality rate of AMI patients during hospitalization and then another study (6) showed 6% lower mortality rate in GIK group. Consistently, inpatient mortality rate was non-significantly low with GIK in both KC-I and -II/III in present study. ECLA trial (7) revealed that GIK infusion significantly decreases 30 day mortality of AMI patients, more prominent with thrombolytic. Another recent study reported that GIK reduced significantly one month mortality rate of AMI patients (1), while present study failed to show any effect for GIK. Solely, Pache et al. (8) found out nonsignificant reduction in the six month mortality rate of MI patients by GIK infusion. The present study not only evaluated the 3 rd , 6 th and 12 th month outcomes, and did not found any effect of GIK on post AMI complications and mortality rate.
Turel et al. (9) reported that GIK with reperfusion therapy significantly decreases post MI HF. In present study, GIK also reduced post AMI HF rate among KC-I, but had no impact on post MI HF in higher KC. Krljanac et al. (6) showed that GIK reduces significantly inpatient recurrent MI in AMI patients (6) , but the present study did not show such effect during follow up. The major study by Diaz et al. (10) was not show any effect of GIK on the one month mortality rate and HF, even outcome in GIK group was worsen during 0-3 days of hospitalization. Differences in the results during early hospitalization may arise from different GIK infusion rate, study population and interval of symptoms onset to treatment. GIK is supposed to provide myocardial protection in patients with AMI during both periods of ischemia and reperfusion (11), but it was reduced the rate of HF during hospitalization in KC-I group.
Finally, the present study is suffering from some limitations including small sample size, undetermined levels of brain natriuretic peptide, C-reactive protein, tumor necrotizing factor alpha, cardiac troponin T, alkaline phosphatase and lactase dehydrogenase.
GIK have not any significant effect on post MI complications and mortality rate during hospitalization, one, three, 12 months after discharging patient from hospital, but it was reduced the development rate of HF during hospitalization in patients with KC-I. Mortality, n(%) 0(0) 0(0) 0(0) 0(0) 0(0) 1 Revascularization PCI, n 2 2 0 1 5 0.470 CABG, n 0 0 1 2 3
Data are presented as proportions/percentages *Chi-square test CABG -coronary artery bypass grafting, GIK -glucose-insulin-potassium, MC -mechanical complications, MCAEs -major cardiac adverse events, MI -myocardial Infarction, PCI -percutaneous coronary intervention, 
